The association between Toll-like receptor 2 single-nucleotide polymorphisms and hepatocellular carcinoma susceptibility

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Junjie, Xie ^a   Songyao, Jiang ^a   Minmin, Shi ^a   Yanyan, Song ^a   Baiyong, Shen ^a   Xiaxing, Deng ^a   Jiabin, Jin ^a   Xi, Zhan ^a   Hao, Chen ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 9;

ADULT; AGED; ARTICLE; CANCER RISK; CANCER STAGING; CANCER SUSCEPTIBILITY; CHINESE; CONTROLLED STUDY; EXON; FALSE POSITIVE RESULT; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HAPLOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HOSPITAL BASED CASE CONTROL STUDY; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; LINKAGE DISEQUILIBRIUM; LIVER NEOPLASMS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; TOLL-LIKE RECEPTOR 2; YOUNG ADULT;

EID: 84856573895     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-57     Document Type: Article

References (32)

1. Andreakos E, Foxwell B, Feldmann M. Is targeting Toll-like receptors and their signaling pathway a useful therapeutic approach to modulating cytokine-driven inflammation?. Immunol Rev 2004, 202:250-265. 10.1111/j.0105-2896.2004.00202.x, 15546398.
2. Yoshioka T, Morimoto Y, Iwagaki H, Itoh H, Saito S, Kobayashi N, Yagi T, Tanaka N. Bacterial lipopolysaccharide induces transforming growth factor beta and hepatocyte growth factor through toll-like receptor 2 in cultured human colon cancer cells. J Int Med Res 2001, 29:409-420.
3. Huang B, Zhao J, Shen S, Li H, He KL, Shen GX, Mayer L, Unkeless J, Li D, Yuan Y, Zhang GM, Xiong H, Feng ZH. Listeria monocytogenes promotes tumor growth via tumor cell toll-like receptor 2 signaling. Cancer Res 2007, 67:4346-4352. 10.1158/0008-5472.CAN-06-4067, 17483348.
4. Testro AG, Visvanathan K. Toll-like receptors and their role in gastrointestinal disease. J Gastroenterol Hepatol 2009, 24:943-954. 10.1111/j.1440-1746.2009.05854.x, 19638078.
5. French SW, Oliva J, French BA, Li J, Bardag-Gorce F. Alcohol, nutrition and liver cancer: role of Toll-like receptor signaling. World J Gastroenterol 2010, 16:1344-1348. 10.3748/wjg.v16.i11.1344, 2842526, 20238401.
6. Thompson AJ, Colledge D, Rodgers S, Wilson R, Revill P, Desmond P, Mansell A, Visvanathan K, Locarnini S. Stimulation of the interleukin-1 receptor and Toll-like receptor 2 inhibits hepatitis B virus replication in hepatoma cell lines in vitro. Antivir Ther 2009, 14:797-808. 10.3851/IMP1294, 19812442.
7. Oliva J, Bardag-Gorce F, French BA, Li J, McPhaul L, Amidi F, Dedes J, Habibi A, Nguyen S, French SW. Fat10 is an epigenetic marker for liver preneoplasia in a drug-primed mouse model of tumorigenesis. Exp Mol Pathol 2008, 84:102-112. 10.1016/j.yexmp.2007.12.003, 2874461, 18280469.
8. Liu X, Xu Q, Chen W, Cao H, Zheng R, Li G. Hepatitis B virus DNA-induced carcinogenesis of human normal liver cells by virtue of nonmethylated CpG DNA. Oncol Rep 2009, 21:941-947.
9. Tanaka J, Sugimoto K, Shiraki K, Tameda M, Kusagawa S, Nojiri K, Beppu T, Yoneda K, Yamamoto N, Uchida K, Kojima T, Takei Y. Functional cell surface expression of toll-like receptor 9 promotes cell proliferation and survival in human hepatocellular carcinomas. Int J Oncol 2010, 37:805-814.
10. Xu N, Yao HP, Sun Z, Chen Z. Toll-like receptor 7 and 9 expression in peripheral blood mononuclear cells from patients with chronic hepatitis B and related hepatocellular carcinoma. Acta Pharmacol Sin 2008, 29:239-244. 10.1111/j.1745-7254.2008.00711.x, 18215354.
11. Srivastava K, Srivastava A, Kumar A, Mittal B. Gallbladder cancer predisposition: a multigenic approach to DNA-repair, apoptotic and inflammatory pathway genes. PLoS One 2011, 6:e16449. 10.1371/journal.pone.0016449, 3025033, 21283657.
12. Pandey S, Mittal RD, Srivastava M, Srivastava K, Singh S, Srivastava S, Mittal B. Impact of Toll-like receptors [TLR] 2 (-196 to -174 del) and TLR 4 (Asp299Gly, Thr399Ile) in cervical cancer susceptibility in North Indian women. Gynecol Oncol 2009, 114:501-505. 10.1016/j.ygyno.2009.05.032, 19541348.
13. Purdue MP, Lan Q, Wang SS, Kricker A, Menashe I, Zheng TZ, Hartge P, Grulich AE, Zhang Y, Morton LM, Vajdic CM, Holford TR, Severson RK, Leaderer BP, Cerhan JR, Yeager M, Cozen W, Jacobs K, Davis S, Rothman N, Chanock SJ, Chatterjee N, Armstrong BK. A pooled investigation of Toll-like receptor gene variants and risk of non-Hodgkin lymphoma. Carcinogenesis 2009, 30:275-281. 2639046, 19029192.
14. Ashton KA, Proietto A, Otton G, Symonds I, McEvoy M, Attia J, Scott RJ. Toll-like receptor (TLR) and nucleosome-binding oligomerization domain (NOD) gene polymorphisms and endometrial cancer risk. BMC Cancer 2010, 10:382. 10.1186/1471-2407-10-382, 2918576, 20646321.
15. Greene FL. AJCC cancer staging manual 2002, 435. Chicago: Springer.
16. Minmin S, Xiaoqian X, Hao C, Baiyong S, Xiaxing D, Junjie X, Xi Z, Jianquan Z, Songyao J. Single nucleotide polymorphisms of toll-like receptor 4 decrease the risk of development of hepatocellular carcinoma. PLoS One 2011, 6:e19466. 10.1371/journal.pone.0019466, 3084862, 21559380.
17. Wacholder S, Chanock S, Garcia-Closas M, El Ghormli L, Rothman N. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst 2004, 96:434-442. 10.1093/jnci/djh075, 15026468.
18. Boraska Jelavić T, Barisić M, Drmic Hofman I, Boraska V, Vrdoljak E, Peruzović M, Hozo I, Puljiz Z, Terzić J. Microsatelite GT polymorphism in the toll-like receptor 2 is associated with colorectal cancer. Clin Genet 2006, 70:156-160. 10.1111/j.1399-0004.2006.00651.x, 16879199.
19. Srivastava K, Srivastava A, Kumar A, Mittal B. Significant association between toll-like receptor gene polymorphisms and gallbladder cancer. Liver Int 2010, 30:1067-1072. 10.1111/j.1478-3231.2010.02268.x, 20492496.
20. Nischalke HD, Coenen M, Berger C, Aldenhoff K, Müller T, Berg T, Krämer B, Körner C, Odenthal M, Schulze F, Grünhage F, Nattermann J, Sauerbruch T, Spengler U. The toll-like receptor 2 (TLR2) -196 to -174 del/ins polymorphism affects viral loads and susceptibility to hepatocellular carcinoma in chronic hepatitis C. Int J Cancer 2011, doi:10.1002/ijc.26143.
21. Egan MF, Straub RE, Goldberg TE, Yakub I, Callicott JH, Hariri AR, Mattay VS, Bertolino A, Hyde TM, Shannon-Weickert C, Akil M, Crook J, Vakkalanka RK, Balkissoon R, Gibbs RA, Kleinman JE, Weinberger DR. Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia. Proc Natl Acad Sci USA 2004, 101:12604-12609. 10.1073/pnas.0405077101, 515104, 15310849.
22. Fedetz M, Matesanz F, Caro-Maldonado A, Fernandez O, Tamayo JA, Guerrero M, Delgado C, López-Guerrero JA, Alcina A. OAS1 gene haplotype confers susceptibility to multiple sclerosis. Tissue Antigens 2006, 68:446-449. 10.1111/j.1399-0039.2006.00694.x, 17092260.
23. Solís-Añez E, Delgado-Luengo W, Borjas-Fuentes L, Zabala W, Arráiz N, Pineda L, Portillo MG, González-Ferrer S, Chacín JA, Peña J, Montiel C, Morales A, Rojas de Atencio A, Cañizales J, González R, Miranda LE, Abreu N, Delgado J. Molecular analysis of the GABRB3 gene in autistic patients: an exploratory study. Invest Clin 2007, 48:225-242.
24. Hunt R, Sauna ZE, Ambudkar SV, Gottesman MM, Kimchi-Sarfaty C. Silent (synonymous) SNPs: should we care about them?. Methods Mol Biol 2009, 578:23-39. 10.1007/978-1-60327-411-1_2, 19768585.
25. Shen LX, Basilion JP, Stanton VP. Single-nucleotide polymorphisms can cause different structural folds of mRNA. Proc Natl Acad Sci USA 1999, 96:7871-7876. 10.1073/pnas.96.14.7871, 22154, 10393914.
26. Cartegni L, Chew SL, Krainer AR. Listening to silence and understanding nonsense: exonic mutations that affect splicing. Nat Rev Genet 2002, 3:285-298. 10.1038/nrg775, 11967553.
27. Chamary JV, Parmley JL, Hurst LD. Hearing silence: non-neutral evolution at synonymous sites in mammals. Nat Rev Genet 2006, 7:98-108. 10.1038/nrg1770, 16418745.
28. Diatchenko L, Slade GD, Nackley AG, Bhalang K, Sigurdsson A, Belfer I, Goldman D, Xu K, Shabalina SA, Shagin D, Max MB, Makarov SS, Maixner W. Genetic basis for individual variations in pain perception and the development of a chronic pain condition. Hum Mol Genet 2005, 14:135-143.
29. Etokebe GE, Knezević J, Petricević B, Pavelić J, Vrbanec D, Dembić Z. Single-nucleotide polymorphisms in genes encoding toll-like receptor -2, -3, -4, and -9 in case-control study with breast cancer. Genet Test Mol Biomarkers 2009, 13:729-734. 10.1089/gtmb.2009.0045, 19810822.
30. Hold GL, Smith MG, McLean MH, Berry S, McColl KE, Mowat A, El Omar EM. Innate immune response gene polymorphisms and their role in H-pylori-induced gastric cancer. Gastroenterology 2006, 130:A61.
31. Hold GL, Rabkin CS, Gammon MD, Berry SH, Smith MG, Lissowska J, Risch HA, Chow WH, Mowat NA, Vaughan TL, El-Omar EM. CD14-159C/T and TLR9-1237T/C polymorphisms are not associated with gastric cancer risk in Caucasian populations. Eur J Cancer Prev 2009, 18:117-119. 10.1097/CEJ.0b013e3283101292, 2679029, 19337058.
32. Zhang H, Zhai Y, Hu Z, Wu C, Qian J, Jia W, Ma F, Huang W, Yu L, Yue W, Wang Z, Li P, Zhang Y, Liang R, Wei Z, Cui Y, Xie W, Cai M, Yu X, Yuan Y, Xia X, Zhang X, Yang H, Qiu W, Yang J, Gong F, Chen M, Shen H, Lin D, Zeng YX, He F, Zhou G. Genome-wide association study identifies 1p36.22 as a new susceptibility locus for hepatocellular carcinoma in chronic hepatitis B virus carriers. Nat Genet 2010, 42:755-758. 10.1038/ng.638, 20676096.